https://orcid.org/0000-0001-7019-4101
References
- Williams GH. Introduction to third edition. In: The Radical Reformation, 3rd Ed; 2020:1–21. doi:10.5325/j.ctv1c9hns8.9
- Martinez AJ. Medical Microbiology. Med Microbiol 4th ed.; 1996:1–9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7627/. Accessed November 12, 2021.
- Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102146. doi:10.1016/J.DSX.2021.05.019
- Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–e421. doi:10.1016/S1473-3099(19)30312-3
- Mallis A, Mastronikolis SN, Naxakis SS, Papadas AT. Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci. 2010;14(11):987–992.
- Song G, Liang G, Liu W. Fungal Co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020;185(4):1. doi:10.1007/S11046-020-00462-9
- Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9). doi:10.7759/CUREUS.10726
- Mitaka H, Kuno T, Takagi H, Patrawalla P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021;64(9):993–1001. doi:10.1111/MYC.13292
- RECOVERY Collaborative Group, Horby P, Lim WS, et al Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/nejmoa2021436
- Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16. doi:10.1093/CID/CIR865
- Bhandari J, Thada PK, Nagalli S. Rhinocerebral Mucormycosis. StatPearls; July 7, 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559288/. Accessed December 3, 2021.
- Novais AG, Capelo J, Costa M, et al. Pulmonary mucormycosis: a case report. IDCases. 2020;22:e00993. doi:10.1016/j.idcr.2020.e00993
- Wotiye AB, Ks P, Ayele BA. Invasive intestinal mucormycosis in a 40-year old immunocompetent patient - A rarely reported clinical phenomenon: a case report. BMC Gastroenterol. 2020;20(1):1–6. doi:10.1186/S12876-020-01202-5
- Jayaramayya K, Mahalaxmi I, Subramaniam MD, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep. 2020;53(8):400–412. doi:10.5483/BMBRep.2020.53.8.121
- Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - case report and review of literature. J Mycol Med. 2021;31(2):101125. doi:10.1016/J.MYCMED.2021.101125
- Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. 2021:112067212110094. doi:10.1177/11206721211009450
- John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for Mucormycosis. J Fungi (Basel, Switzerland). 2021;7(4). doi:10.3390/JOF7040298
- Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395–402. doi:10.1093/MMY/MYY060
- Sen M, Honavar S, Sengupta S, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021;69(7):1670–1692. doi:10.4103/IJO.IJO_1565_21
- Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5–264.e8. doi:10.1016/J.AJEM.2020.09.032
- Holmes TR, Hepschke JL, Jacobson I, Maloof A. Mucormycosis: early treatment is the key to survival. Med J Aust. 2021;215(9):401–403. doi:10.5694/mja2.51290
- Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18. doi:10.1016/S1473-3099(16)30541-2
- Scriven JE, Tenforde MW, Levitz SM, Jarvis JN. Modulating host immune responses to fight invasive fungal infections. Curr Opin Microbiol. 2017;40:95–103. doi:10.1016/j.mib.2017.10.018